Furthermore, the mean insulin doses and the mean basal/bolus ratio remained constant, supporting the findings from randomized controlled trials that patients could benefit solely from switching bolus insulin.3,4 Overall, our findings support the treatment switch to faster aspart in combination with iscCGM in insulin-experienced patients with T1D, particularly in those in need of better glycemic control and/or more flexible bolus administration. This evidence concerns the gene INS and type 1 diabetes mellitus.